_id	KpiId	KpiName	Value	DataType	Period	StartDate	EndDate	CollectionFrequency
1	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.90 %	Percentage	2013/2014_Q1	2013-04-01	2013-06-30	Quarterly
2	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.60 %	Percentage	2013/2014	2013-04-01	2014-03-31	Quarterly
3	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2013/2014_Q2	2013-07-01	2013-09-30	Quarterly
4	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.50 %	Percentage	2013/2014_Q3	2013-10-01	2013-12-31	Quarterly
5	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.60 %	Percentage	2013/2014_Q4	2014-01-01	2014-03-31	Quarterly
6	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	36.50 %	Percentage	2014/2015_Q1	2014-04-01	2014-06-30	Quarterly
7	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	40.10 %	Percentage	2014/2015	2014-04-01	2015-03-31	Quarterly
8	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	35.60 %	Percentage	2014/2015_Q2	2014-07-01	2014-09-30	Quarterly
9	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.80 %	Percentage	2014/2015_Q3	2014-10-01	2014-12-31	Quarterly
10	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	40.10 %	Percentage	2014/2015_Q4	2015-01-01	2015-03-31	Quarterly
11	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.00 %	Percentage	2015/2016_Q1	2015-04-01	2015-06-30	Quarterly
12	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2015/2016	2015-04-01	2016-03-31	Quarterly
13	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.80 %	Percentage	2015/2016_Q2	2015-07-01	2015-09-30	Quarterly
14	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	33.30 %	Percentage	2015/2016_Q3	2015-10-01	2015-12-31	Quarterly
15	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2015/2016_Q4	2016-01-01	2016-03-31	Quarterly
16	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.51 %	Percentage	2016/2017_Q1	2016-04-01	2016-06-30	Quarterly
17	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.08 %	Percentage	2016/2017	2016-04-01	2017-03-31	Quarterly
18	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	37.93 %	Percentage	2016/2017_Q2	2016-07-01	2016-09-30	Quarterly
19	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	37.89 %	Percentage	2016/2017_Q3	2016-10-01	2016-12-31	Quarterly
20	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.08 %	Percentage	2016/2017_Q4	2017-01-01	2017-03-31	Quarterly
21	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.11 %	Percentage	2017/2018	2017-04-01	2018-03-31	Quarterly
22	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	36.93 %	Percentage	2017/2018_Q1	2017-04-01	2017-06-30	Quarterly
23	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	33.91 %	Percentage	2017/2018_Q2	2017-07-01	2017-09-30	Quarterly
24	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.96 %	Percentage	2017/2018_Q3	2017-10-01	2017-12-31	Quarterly
25	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.11 %	Percentage	2017/2018_Q4	2018-01-01	2018-03-31	Quarterly
26	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.20 %	Percentage	2018/2019	2018-04-01	2019-03-31	Quarterly
27	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.33 %	Percentage	2018/2019_Q1	2018-04-01	2018-06-30	Quarterly
28	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.61 %	Percentage	2018/2019_Q2	2018-07-01	2018-09-30	Quarterly
29	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.50 %	Percentage	2018/2019_Q3	2018-10-01	2018-12-31	Quarterly
30	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.20 %	Percentage	2018/2019_Q4	2019-01-01	2019-03-31	Quarterly
31	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.71 %	Percentage	2019/2020_Q1	2019-04-01	2019-06-30	Quarterly
32	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.71 %	Percentage	2019/2020	2019-04-01	2020-03-31	Quarterly
33	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.49 %	Percentage	2019/2020_Q2	2019-07-01	2019-09-30	Quarterly
34	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.84 %	Percentage	2019/2020_Q3	2019-10-01	2019-12-31	Quarterly
35	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.71 %	Percentage	2019/2020_Q4	2020-01-01	2020-03-31	Quarterly
36	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021	2020-04-01	2021-03-31	Quarterly
37	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021_Q1	2020-04-01	2020-06-30	Quarterly
38	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.67 %	Percentage	2020/2021_Q2	2020-07-01	2020-09-30	Quarterly
39	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.97 %	Percentage	2020/2021_Q3	2020-10-01	2020-12-31	Quarterly
40	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021_Q4	2021-01-01	2021-03-31	Quarterly
41	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.50 %	Percentage	2021/2022	2021-04-01	2022-03-31	Quarterly
42	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.61 %	Percentage	2021/2022_Q1	2021-04-01	2021-06-30	Quarterly
43	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.70 %	Percentage	2021/2022_Q2	2021-07-01	2021-09-30	Quarterly
44	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.73 %	Percentage	2021/2022_Q3	2021-10-01	2021-12-31	Quarterly
45	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.50 %	Percentage	2021/2022_Q4	2022-01-01	2022-03-31	Quarterly
46	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	20.00 %	Percentage	2022/2023	2022-04-01	2023-03-31	Quarterly
47	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	24.78 %	Percentage	2022/2023_Q1	2022-04-01	2022-06-30	Quarterly
48	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	21.40 %	Percentage	2022/2023_Q2	2022-07-01	2022-09-30	Quarterly
49	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.92 %	Percentage	2022/2023_Q3	2022-10-01	2022-12-31	Quarterly
50	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	20.00 %	Percentage	2022/2023_Q4	2023-01-01	2023-03-31	Quarterly
51	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	21.99 %	Percentage	2023/2024_Q1	2023-04-01	2023-06-30	Quarterly
52	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.52 %	Percentage	2023/2024	2023-04-01	2024-03-31	Quarterly
53	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	22.22 %	Percentage	2023/2024_Q2	2023-07-01	2023-09-30	Quarterly
54	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	23.30 %	Percentage	2023/2024_Q3	2023-10-01	2023-12-31	Quarterly
55	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.52 %	Percentage	2023/2024_Q4	2024-01-01	2024-03-31	Quarterly
56	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	16.50 %	Percentage	2024/2025_Q1	2024-04-01	2024-06-30	Quarterly
57	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.14 %	Percentage	2024/2025	2024-04-01	2025-03-31	Quarterly
58	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.70 %	Percentage	2024/2025_Q2	2024-07-01	2024-09-30	Quarterly
59	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	15.84 %	Percentage	2024/2025_Q3	2024-10-01	2024-12-31	Quarterly
60	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.14 %	Percentage	2024/2025_Q4	2025-01-01	2025-03-31	Quarterly
61	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	18.72 %	Percentage	2025/2026_Q1	2025-04-01	2025-06-30	Quarterly
62	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	23.59 %	Percentage	2025/2026_Q2	2025-07-01	2025-09-30	Quarterly
63	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.90 %	Percentage	2013/2014_Q1	2013-04-01	2013-06-30	Quarterly
64	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.60 %	Percentage	2013/2014	2013-04-01	2014-03-31	Quarterly
65	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2013/2014_Q2	2013-07-01	2013-09-30	Quarterly
66	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.50 %	Percentage	2013/2014_Q3	2013-10-01	2013-12-31	Quarterly
67	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.60 %	Percentage	2013/2014_Q4	2014-01-01	2014-03-31	Quarterly
68	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	36.50 %	Percentage	2014/2015_Q1	2014-04-01	2014-06-30	Quarterly
69	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	40.10 %	Percentage	2014/2015	2014-04-01	2015-03-31	Quarterly
70	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	35.60 %	Percentage	2014/2015_Q2	2014-07-01	2014-09-30	Quarterly
71	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.80 %	Percentage	2014/2015_Q3	2014-10-01	2014-12-31	Quarterly
72	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	40.10 %	Percentage	2014/2015_Q4	2015-01-01	2015-03-31	Quarterly
73	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.00 %	Percentage	2015/2016_Q1	2015-04-01	2015-06-30	Quarterly
74	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2015/2016	2015-04-01	2016-03-31	Quarterly
75	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	34.80 %	Percentage	2015/2016_Q2	2015-07-01	2015-09-30	Quarterly
76	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	33.30 %	Percentage	2015/2016_Q3	2015-10-01	2015-12-31	Quarterly
77	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.10 %	Percentage	2015/2016_Q4	2016-01-01	2016-03-31	Quarterly
78	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.51 %	Percentage	2016/2017_Q1	2016-04-01	2016-06-30	Quarterly
79	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.08 %	Percentage	2016/2017	2016-04-01	2017-03-31	Quarterly
80	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	37.93 %	Percentage	2016/2017_Q2	2016-07-01	2016-09-30	Quarterly
81	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	37.89 %	Percentage	2016/2017_Q3	2016-10-01	2016-12-31	Quarterly
82	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	38.08 %	Percentage	2016/2017_Q4	2017-01-01	2017-03-31	Quarterly
83	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.11 %	Percentage	2017/2018	2017-04-01	2018-03-31	Quarterly
84	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	36.93 %	Percentage	2017/2018_Q1	2017-04-01	2017-06-30	Quarterly
85	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	33.91 %	Percentage	2017/2018_Q2	2017-07-01	2017-09-30	Quarterly
86	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.96 %	Percentage	2017/2018_Q3	2017-10-01	2017-12-31	Quarterly
87	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.11 %	Percentage	2017/2018_Q4	2018-01-01	2018-03-31	Quarterly
88	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.20 %	Percentage	2018/2019	2018-04-01	2019-03-31	Quarterly
89	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	30.33 %	Percentage	2018/2019_Q1	2018-04-01	2018-06-30	Quarterly
90	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.61 %	Percentage	2018/2019_Q2	2018-07-01	2018-09-30	Quarterly
91	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.50 %	Percentage	2018/2019_Q3	2018-10-01	2018-12-31	Quarterly
92	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.20 %	Percentage	2018/2019_Q4	2019-01-01	2019-03-31	Quarterly
93	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.71 %	Percentage	2019/2020_Q1	2019-04-01	2019-06-30	Quarterly
94	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.71 %	Percentage	2019/2020	2019-04-01	2020-03-31	Quarterly
95	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	32.49 %	Percentage	2019/2020_Q2	2019-07-01	2019-09-30	Quarterly
96	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	31.84 %	Percentage	2019/2020_Q3	2019-10-01	2019-12-31	Quarterly
97	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.71 %	Percentage	2019/2020_Q4	2020-01-01	2020-03-31	Quarterly
98	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021	2020-04-01	2021-03-31	Quarterly
99	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021_Q1	2020-04-01	2020-06-30	Quarterly
100	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.67 %	Percentage	2020/2021_Q2	2020-07-01	2020-09-30	Quarterly
101	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.97 %	Percentage	2020/2021_Q3	2020-10-01	2020-12-31	Quarterly
102	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.30 %	Percentage	2020/2021_Q4	2021-01-01	2021-03-31	Quarterly
103	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.50 %	Percentage	2021/2022	2021-04-01	2022-03-31	Quarterly
104	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	27.61 %	Percentage	2021/2022_Q1	2021-04-01	2021-06-30	Quarterly
105	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	29.70 %	Percentage	2021/2022_Q2	2021-07-01	2021-09-30	Quarterly
106	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	28.73 %	Percentage	2021/2022_Q3	2021-10-01	2021-12-31	Quarterly
107	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	26.50 %	Percentage	2021/2022_Q4	2022-01-01	2022-03-31	Quarterly
108	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	20.00 %	Percentage	2022/2023	2022-04-01	2023-03-31	Quarterly
109	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	24.78 %	Percentage	2022/2023_Q1	2022-04-01	2022-06-30	Quarterly
110	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	21.40 %	Percentage	2022/2023_Q2	2022-07-01	2022-09-30	Quarterly
111	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.92 %	Percentage	2022/2023_Q3	2022-10-01	2022-12-31	Quarterly
112	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	20.00 %	Percentage	2022/2023_Q4	2023-01-01	2023-03-31	Quarterly
113	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	21.99 %	Percentage	2023/2024_Q1	2023-04-01	2023-06-30	Quarterly
114	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.52 %	Percentage	2023/2024	2023-04-01	2024-03-31	Quarterly
115	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	22.22 %	Percentage	2023/2024_Q2	2023-07-01	2023-09-30	Quarterly
116	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	23.30 %	Percentage	2023/2024_Q3	2023-10-01	2023-12-31	Quarterly
117	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	19.52 %	Percentage	2023/2024_Q4	2024-01-01	2024-03-31	Quarterly
118	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	16.50 %	Percentage	2024/2025_Q1	2024-04-01	2024-06-30	Quarterly
119	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.14 %	Percentage	2024/2025	2024-04-01	2025-03-31	Quarterly
120	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.70 %	Percentage	2024/2025_Q2	2024-07-01	2024-09-30	Quarterly
121	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	15.84 %	Percentage	2024/2025_Q3	2024-10-01	2024-12-31	Quarterly
122	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	17.14 %	Percentage	2024/2025_Q4	2025-01-01	2025-03-31	Quarterly
123	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	18.72 %	Percentage	2025/2026_Q1	2025-04-01	2025-06-30	Quarterly
124	PHOF77	% of non-opiate users in treatment who successfully completed drug treatment (without representation within 6 months)	23.59 %	Percentage	2025/2026_Q2	2025-07-01	2025-09-30	Quarterly